Showing results (131-140 of 617) with videos related to
Sort By:
Pageof 62
Medizinische Klinik (Munich, Germany : 1983)|February 8, 2002
[Drug therapy of chronic myeloid leukemia]Andreas Hochhaus, Ute Berger, Andreas Reiter, et al.Membranes|July 25, 2022
Wicking in Porous Polymeric Membranes: Determination of an Effective Capillary Radius to Predict the Flow Behavior in Lateral Flow AssaysPatrick Altschuh, Willfried Kunz, Marcel Bremerich, et al.Seminars in Hematology|March 28, 2012
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemiasPeter Valent, Hans-Peter Horny, Bruce S Bochner, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 2014
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisVikas Gupta, Jason Gotlib, Jerald P Radich, et al.Journal of Oncology Practice|August 15, 2013
Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical centerBrett E Glotzbecker, Deborah S Yolin-Raley, Daniel J DeAngelo, et al.Blood Reviews|February 22, 2023
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDSStacey M Frumm, Shai Shimony, Richard M Stone, et al.G3 (Bethesda, Md.)|August 13, 2017
Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in Caenorhabditis elegans and Homo sapiensMassa J Shoura, Idan Gabdank, Loren Hansen, et al.Leukemia Research|December 3, 2014
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemiaMichaela Liedtke, Tamara Dunn, Shira Dinner, et al.Blood Cancer Discovery|July 27, 2023
Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery ApproachesPramod C Nair, Jacob Piehler, Denis Tvorogov, et al.The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.Pageof 62